Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy
Brief Summary: A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of Crohn's disease.


Options:
A: Arm Label: Placebo (IP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (IP) | Arm Label: Ustekinumab 1mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 1mg/kg (IP) | Arm Label: Ustekinumab 3 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 3 mg/kg (IP) | Arm Label: Ustekinumab 6 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 6 mg/kg (IP) | Arm Label: Placebo IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Responder - Placebo SC (MP) | Arm Label: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP) | Arm Label: Ustekinumab IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Responder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Placebo (IP); Assigned to Arm(s): Placebo (IP) | Intervention Type: DRUG; Name: Ustekinumab 1mg/kg (IP); Assigned to Arm(s): Ustekinumab 1mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 3 mg/kg (IP); Assigned to Arm(s): Ustekinumab 3 mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 6 mg/kg (IP); Assigned to Arm(s): Ustekinumab 6 mg/kg (IP) | Intervention Type: DRUG; Name: Placebo IV - Responder - Placebo SC (MP); Assigned to Arm(s): Placebo IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP); Assigned to Arm(s): Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
B: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
C: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
D: Arm Label: Population 1: Placebo SC followed by ustekinumab SC; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Placebo SC | Arm Label: Population 1: Ustekinumab SC followed by Placebo SC:; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Placebo SC | Arm Label: Population 1: Placebo IV followed by ustekinumab IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg, Drug: Placebo IV | Arm Label: Population 1: Ustekinumab IV followed by Placebo IV:; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg, Drug: Placebo IV | Arm Label: Population 2: Ustekinumab SC; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg | Arm Label: Population 2: Ustekinumab IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Population 1: Placebo SC followed by ustekinumab SC, Population 1: Ustekinumab SC followed by Placebo SC:, Population 2: Ustekinumab SC | Intervention Type: DRUG; Name: Ustekinumab 4.5 mg/kg; Assigned to Arm(s): Population 1: Placebo IV followed by ustekinumab IV, Population 1: Ustekinumab IV followed by Placebo IV:, Population 2: Ustekinumab IV | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): Population 1: Placebo SC followed by ustekinumab SC, Population 1: Ustekinumab SC followed by Placebo SC: | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Population 1: Placebo IV followed by ustekinumab IV, Population 1: Ustekinumab IV followed by Placebo IV:

Answer: A